Editor’s Note: The original article incorrectly references Lucentis’ and Eylea’s dosage instructions and Roche’s vaccine market share. This has been corrected and Motley Fool sincerely apologizes for the error.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) should spike– every time there’s a slight pullback the stock shoots higher. Last Thursday Regeneron gained almost 10% behind a positive Phase 3 trial for its drug Eylea.
Regeneron Pharmaceuticals is a $25 billion biopharmaceutical company with three approved products and annual sales of $1.59 billion. Right away, that ratio not might look right, as a $25 billion company should have more revenue than $1.59 billion. But, its stock price is counting on growth, as it has 13 products being tested in clinical trials, and three different drugs in Phase 3 (five total studies).
Taking a look at Eylea
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is one of the most promising drug companies in the market, and it is because of Eylea. Currently, Eylea is used to treat “wet” age-related macular degeneration, the leading cause of blindness in the elderly. It is approved in the U.S., and Regeneron markets the drug exclusively – but Bayer markets the drug oversees and receives a royalty on oversees revenue.
While Regeneron and Bayer are partners in developing and marketing Eylea, there’s no question Eylea has been developed using the technology of Regeneron and is primarily Regeneron’s drug. Its most direct competition comes from RocheHoldings‘ drug Lucentis. When Eylea was launched many feared that it would not be able to compete with the presence of Roche and its drug.
Eylea set to expand
Eylea is quickly replacing all competition (including Roche’s Lucentis) as both Regeneron and Bayer have done a great job marketing the drug. Not to mention, Eylea is superior in that it only has to be injected once every two months; compared to monthly like other drugs.
However, there is another drug in the works that must be mentioned, and that is Ampio Pharmaceuticals Inc (NASDAQ:AMPE)’ drug Optina. This drug treats the same condition, but instead of a needle to the eye, it is taken in pill form to repair blood vessels. But, Optina is still in clinical trials, awaiting data, and there are serious doubts the drug will be effective.
If Regeneron Pharmaceuticals Inc (NASDAQ:REGN) believed Optina would challenge its future sales, there’s no doubt it would buy the company. Ampio trades at a market cap of just $220 million while Regeneron is a $25 billion powerhouse. And Regeneron has an incredible pipeline along with a drug that is growing and expanding. In short, it has the cash.